Free Trial

NeoGenomics Q3 2023 Earnings Report

NeoGenomics logo
$17.55 -0.42 (-2.34%)
(As of 12/17/2024 ET)

NeoGenomics EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

NeoGenomics Revenue Results

Actual Revenue
$151.95 million
Expected Revenue
$142.15 million
Beat/Miss
Beat by +$9.80 million
YoY Revenue Growth
N/A

NeoGenomics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

A conspiracy Trump won’t unseal (Ad)

New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.

This is the untold, true story of God’s Investment.

NeoGenomics Earnings Headlines

A conspiracy Trump won’t unseal
New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.
NeoGenomics price target raised to $19 from $18 at BofA
See More NeoGenomics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NeoGenomics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeoGenomics and other key companies, straight to your email.

About NeoGenomics

NeoGenomics (NASDAQ:NEO) operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

View NeoGenomics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings